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Abstract 
Background: According to Warburg’s effect, the rate of glycolysis increases in cancerous cells. This will increase 
overall levels of pyruvic acid. The present on-going study was conducted to estimate the levels of pyruvic acid in 
saliva and serum in normal, oral PMD subjects.
Material and Methods: A total of 50 subjects in healthy, PMD of the oral cavity individuals were selected based on 
clinical and histological criteria. Collected saliva and serum samples were subjected to pyruvic acid level estima-
tion using biochemical analysis.
Results: Of the 50 participants 25 (13: Males; 12: Females) & 25 (16: Males; 9: Females) were PMD group. Inde-
pendent samples t test showed statistically significant difference in serum & salivary pyruvic acid level in between 
2 groups (P < 0.001 respectively) 
Conclusions: Estimation of pyruvic acid showed sequential increase in the level in PMD group compared to healthy. 
Hence the study results open new direction in cancer screening.
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Introduction
It has been well established by researchers that virtually 
all oral cancer are preceded by visible clinical changes 
in the oral mucosa, usually in the form of white or red 
patch. World Health Organization (WHO) (2005) chan-
ged the terminology of premalignant condition and le-
sion into poetically malignant disorder (PMD) (1). PMD 
includes many oral conditions like Oral leukoplakia, Oral 
lichen planus, Actiniccheilitis, Oral Submucous fibrosis 
and many more, out of which leukoplakia and erythro-
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plakia are the most common ones. These diagnoses are 
still based on the white and red lesion in the oral cavity 
(1). Approximately 70% of oral carcinomas detected by 
visual inspection (2). At present there are many cancer 
screening techniques including routine clinical exami-
nation, toluidine blue staining, tissue auto fluorescence, 
oral brush biopsy (3). But these methods have their own 
limitations such as Acceptability, Affordability and Ac-
cessibility and also patients seeking attention, and delays 
in medical and dental practitioners referring patients for 
diagnosis and treatment have been noted as important 
factors for possible delay in diagnosis (4).
In spite of tremendous progress in the field of molecu-
lar biology there is yet no single marker that reliably 
enables to predict malignant transformation in an indi-
vidual patient (1) in more objectively. Therefore there is 
a need to think a technique of screening which mask all 
the limitations of the present screening method. Among 
the products of metabolism, pyruvic acid is of great im-
portance because it is an intermediary in carbohydrate, 
as well as in protein and in fat metabolism. None of the 
studies estimated the pyruvate changes in PMD and oral 
cancer. It has been observed that cancer cells frequently 
disclose increase glycolysis and depend largely on this 
metabolic pathway for generation of ATP to meet their 
energy requirements (5). However, whether the increase 
of glycolytic activity in cancer cells is mainly due to in-
herent metabolic alterations or due to anaerobic environ-
ment in the tumour tissues remains controversial (6,7).
Estimating the level of pyruvic acid in saliva and serum 
might reflect the spectrum of oral cancer. Hence the aim 
of the present on-going study is to estimate and compare 
the levels of pyruvic acid in saliva and serum in normal, 
oral PMD subjects.
Material and Methods 
Following approval from the SDM College of Dental 
Sciences and Hospital Ethics Committee, recruitment 
was via patients attending the oral medicine outpatient 
clinic at SDM College of Dental Sciences and Hospital. 
Data were collected over 2 month period, by one student 
researchers and one academic researcher. A convenience 
sample was used, with as many patients recruited as pos-
sible within the available timeframe.
Two groups, i.e. Healthy & PMD were selected based 
on confirmed clinical and histological reports. Subjects 
above 40 years of age and those who give informed con-
sent were selected for the study. Those who give nega-
tive clinical report were recruited in the Healthy group, 
whereas subjects with positive clinical and histological 
reports, irrespective of grades and stages were recruited 
in the PMD group. Oral Sub Mucous Fibrosis was iden-
tified only through clinical diagnostic method, as biopsy 
was contraindicated in those cases. Newly diagnosed 
PMD were included in the study. Exclusion criteria in-
cluded systemic diseases like Cardiac diseases, diabetes 
and other carbohydrate metabolic disorders and subjects 
under chemotherapy, radiotherapy and surgery. Demo-
graphic data and Data regarding the personal habits, me-
dication, past dental and medical history were collected 
from all the two groups. Once the subject selected for 
the study, subjects were asked to give 3ml of unstimula-
ted saliva and 5 ml of venous blood.
Immediately saliva and blood samples were kept in deep 
freeze to reduce the rate of biochemical and bacterial 
reactions and transferred to the biochemical laboratory 
within one hour of sample collection.
Biochemical Procedure: 
Blood Pyruvate Quantification is performed by the mo-
dified Di Nitro Phenyl Hydrazine (DNPH) procedure 
proposed by Landon J, Fawcett JK, and Wynn V. whe-
reas in Salivary Pyruvate Estimation first 2 steps were 
bypassed due to fewer amounts of protein levels in sali-
va when compared to serum.
On comparing Healthy with PMD, Independent sample t 
test was used to measure the statistical significant diffe-
rence between two groups.
Results
In total,50 subjects were recruited. Of the participants 25 
(13: Males; 12: Females) & 25 (16: Males; 9: Females) 
were PMD group. The mean age of healthy group was 
53.8 and PMD group was 52.6 (Table 1).
Healthy PMD
Males 13 16
Females 12 9
Mean age 53.8 52.6
Table 1. Gender and mean age distribution.
-Comparison of Serum Pyruvic acid levels of Healthy 
with PMD
Serum pyruvic acid levels of healthy group was 1.15 ± 
0.15 and for PMD, it was 1.45 ± 0.25.Independent Sam-
ple t test showed statistically significant diff. between 
the groups (P < 0.001) (Table 2) (Fig. 1).
-Comparison of Salivary Pyruvic acid levels of Healthy 
with PMD
A clear differentiation between the Healthy and PMD 
was seen (with P < 0.001 for saliva) with the much grea-
ter mean Pyruvic acid levels in PMD subjects (Healthy: 
(1.57 ± 0.15) & PMD: (1.8 ± 1.4)) (Table 2) (Fig. 2).
Discussion
In normal physiologic condition, Pyruvic acid produced 
by Glycolysis cycle will be utilized by Kreb’s Cycle in 
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Fig. 1. Pyruvic acid levels in serum of Healthy and PMC 
individuals.
Mean 
difference
Std. Error 
Difference
Sig. (2-tailed)
Serum -.30160 .05789 .000*
Saliva -.23520 .04070 .000*
Table 2. Independent Samples Test on Healthy and PMD group.
*Significant association set at ≤0.05.
Fig. 2. Pyruvic acid levels in saliva of Healthy and PMC 
individuals.
mitochondria for further ATP production. ATP is syn-
thesized by oxidative phosphorylation in mitochondria; 
which is efficient metabolic process and it produces 
more ATP molecules from a given amount of glucose 
when compared to glycolysis. However, this method of 
production of ATPs is compromised in cancer cells. Hen-
ce cells are able to adapt alternative metabolic pathway 
such as increased glycolytic pathway to maintain their 
energy supply. Cancer cell shows changes not only in 
the glycolytic pathway but also the Krebs cycle, b-oxi-
dation and anabolic metabolism in general are reoriented 
to respond to the new primary function of the cell (i.e. 
Uncontrolled proliferation) by providing not only ener-
gy, but also the synthesis of nucleotides and amino and 
fatty acids (8-12).
Mitochondrial respiratory function can be compromised 
by many factors. Some of the factors include mutations 
in mitochondrial DNA (mtDNA), malfunction of the 
electron transport chain, aberrant expression of enzymes 
involved in energy metabolism, and insufficient oxygen 
available in the cellular microenvironment. Mitochon-
drial DNA contains displacement loops, which has the 
coding sequence, which is responsible the production of 
13 important protein components of mitochondrial res-
piratory complexes (6).
Warburg’s effect can also be initiated by Hypoxia as the 
rate of angiogenesis is comparatively less than that of the 
rate of growth of tumour, this will induce depleted oxy-
gen environment in neoplastic area and induces alterna-
tive respiratory method for the energy production and its 
survival (6) i.e. Glycolysis pathway.  Hence Glycolysis 
is a central metabolic pathway that finely regulates cell 
proliferation by adapting the cancer cell’s metabolism to 
the conditions of its current selective situation (13-17).
Increased glycolytic rate produces more of its end pro-
ducts like Pyruvic acid and Lactic acid. As lactic acid is 
unstable compound, it converts back to pyruvate. This 
leads to increase the overall the levels of pyruvic acid. 
This excess pyruvic acid either leaches into blood or 
local region (oral cavity). Therefore quantification of 
pyruvic acid might give the proportional level of severi-
ty of the PMD. Hence we used Quantification of Pyruvic 
acid for this study. 
The blood pyruvic acid estimation was performed by the 
hydrazin method of Lu and of Friedemann-Haugen. The 
mean blood pyruvate level in the present study came up 
to 1.15 ± 0.15 mg which is similar to the level estimated 
using a hydrazone method by Bueding and Wortis  i.e. 
0.98 ±0.09 mg in 60 fasted subjects (10).
Salivary pyruvic acid level for normal individuals was 
not established till now but in the present study the level 
came up to 1.460 ± 0.64. This is slightly elevated than 
the serum levels, as oral bacteria belongs to prokaryotic 
type of family, they do not possess mitochondria (18) 
and uses only glycolysis pathway for their energy requi-
rement and survival.
The present study result showed elevated Pyruvic acid le-
vel in saliva than in serum, this may be because in serum 
pyruvic acid levels get balanced with the process of 
Cori’s cycle  occurring in liver and another reason might 
be leaching out of Pyruvic acid may be more common to 
local region (Saliva) than the systemic (Serum). Further 
studies require in this direction to prove this hypothe-
sis. The present research is an on-going study,we did not 
consider the severity of PMD as there was no common 
Stratification system for all type of PMD. This may have 
some influence on the study result. 
Future directions 
• Warburg’s effect is common in most of the cancers; this 
principle can be used not only in screening procedures 
of the oral cancer but also other cancers.
• Saliva will play a major role in cancer detection as it 
J Clin Exp Dent. 2015;7(4):e462-5.                                                                                                                                                                    Pyruvic acid estimation in cancer screenin
e465
provides noninvasive significant results. Salivary estima-
tion of Pyruvic acid is comparatively more economical 
and less technique sensitive than the Serum estimation.
Conclusions
The present study is an ongoing research with limited 
number of sample; continuation of the full-fledged pre-
sent study with larger samples is going on in our de-
partments. There were significant increases in pyruvic 
acid levels in the PMD, which can be further utilized 
for the development of a screening tool for the PMD or 
malignancy. The spectrum of cancer begins with healthy 
(Normal) tissue to PMD at subclinical state to full blown 
malignancy. This progression is shown in an ordinal fas-
hion. Thus further studies should be performed to set the 
threshold of pyruvic acid level in each group at different 
stages.
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